Autism Spectrum DisorderNCT00549731
Participant Database for Autism Research Studies
An observational study of Autism Spectrum Disorder, run by Massachusetts General Hospital at 1 site in United States.
Trial summary
The purpose of this study is to create a subject database to recruit for current and future studies in research on autism and other neurodevelopmental disabilities. Read more about this study
- Who is it for?
- Ages 14 to 32 yearsHealthy volunteers can take part
- Conditions the study is for
- Autism Spectrum Disorder
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2013to Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 32 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Adult/Pediatric
Who may be able to join
- Typically-developing, healthy adolescents and adults (ages 14-32)
- Adolescents and adults with autism spectrum disorder (ages 14-32)
Who cannot join
- Extreme premature birth (<34 weeks)
- Known genetic disorders related to autism (e.g. Fragile X)
- Recent diagnosis of psychosis (within 6 months)
- Some other psychiatric diagnoses may be excluded following screening (e.g. Tourette's syndrome).
- Metal implants / permanent retainers / hair dyes with metallic components
Trial locations and contacts
1 site in 1 country.
United States1 site
Martinos Center of Biomedical Imaging
Charlestown, Massachusetts, 02129
About this study
Official title: Database for Persons Interested in Research Studies of Developmental Disorders
The purpose of this study is to create a subject database to recruit for current and future studies in research on autism and other neurodevelopmental disabilities.
Read the detailed description
Aim 1: to recruit people interested in research on autism and other neurodevelopmental disabilities
Aim 2: to complete a diagnostic assessment, to confirm the diagnosis of autism spectrum disorder or other developmental disability (e.g., developmental language delay) in our patient population and rule out a diagnosis of autism spectrum disorder and other comorbid conditions in our control group
Aim 3: to maintain subject information in a database, from which we can recruit for our studies
- Conditions
- Autism Spectrum Disorder
- Keywords
- autism, autistic, language, development, developmental, assessment
- Medical subject headings
- Autism Spectrum Disorder, Autistic Disorder, Language
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy individuals | No intervention Healthy participants ages 14-32 for a neuroimaging study. | |
| Individuals with Autism Spectrum Disorder | No intervention ASD participants ages 14-32 for a neuroimaging study. |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2007 (estimated)
- Study startJun 2013
- Primary completionJun 2023
- Study completionJun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
- Responsible party
- Principal investigator, Tal Kenet, Massachusetts General Hospital
- Investigators
- Tal Kenet, Ph.D, Principal investigator, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00549731
- Sponsor's protocol ID
- 2007-P-000062
- Other IDs
- 5R01MH117998
- Status last verified
- Apr 2026
- First submitted
- 15 Oct 2007
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Database for Persons Interested in Research Studies of Developmental Disorders
- ClinicalTrials.gov ID
- NCT00549731
- Acronym / sponsor ID
- 2007-P-000062
- Conditions
- Autism Spectrum Disorder
- Keywords
- autism, autistic, language, development, developmental, assessment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
- Study start
- Jun 2013 (actual)
- Primary completion
- Jun 2023 (actual)
- Study completion
- Jun 2023 (actual)
- First posted
- 26 Oct 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to create a subject database to recruit for current and future studies in research on autism and other neurodevelopmental disabilities.
Detailed description
Aim 1: to recruit people interested in research on autism and other neurodevelopmental disabilities
Aim 2: to complete a diagnostic assessment, to confirm the diagnosis of autism spectrum disorder or other developmental disability (e.g., developmental language delay) in our patient population and rule out a diagnosis of autism spectrum disorder and other comorbid conditions in our control group
Aim 3: to maintain subject information in a database, from which we can recruit for our studies
Study design
- Observational model
- Other
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Healthy individuals | – | –No intervention Healthy participants ages 14-32 for a neuroimaging study. |
| Individuals with Autism Spectrum Disorder | – | –No intervention ASD participants ages 14-32 for a neuroimaging study. |
Who may qualify
- Ages
- 14 to 32 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Adult/Pediatric
Key inclusion criteria (2 listed)
- Typically-developing, healthy adolescents and adults (ages 14-32)
- Adolescents and adults with autism spectrum disorder (ages 14-32)
Key exclusion criteria (5 listed)
- Extreme premature birth (<34 weeks)
- Known genetic disorders related to autism (e.g. Fragile X)
- Recent diagnosis of psychosis (within 6 months)
- Some other psychiatric diagnoses may be excluded following screening (e.g. Tourette's syndrome).
- Metal implants / permanent retainers / hair dyes with metallic components
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Related trials for Autism Spectrum Disorder
Not yet recruiting
Single Session Support for Parents of Children With Neurodevelopmental Disabilities Struggling With Anxious Avoidance
Neurodevelopmental Disorders, Autism Spectrum Disorder (ASD)
Not yet recruiting
Evaluation of a Novel Quantum-Inspired Intervention (QII) for Children With Autism Spectrum Disorder: A Global Confirmatory Study
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD
Recruiting
Strategies for Toddler ASD With Remote-therapy (STAR) Model for ASD
Autism Spectrum Disorder, Therapy
Recruiting
Smith Magenis Syndrome and Autism Spectrum Disorders
Smith-Magenis Syndrome, Autism Spectrum Disorder
Active, not recruitingPhase 1
Psilocybin for Treatment-Resistant Depression in Autism
Treatment Resistant Depression, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tal Kenet, Ph.D principal investigator
Massachusetts General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autism Spectrum Disorder, run by Massachusetts General Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.